Strengthening regulatory systems
The work of regulatory authorities at national, local, and global levels is vital to make sure safe, effective, and quality-assured medical products are always available at the right time.
Our members in the innovative pharmaceutical industry work closely with national and regional regulatory authorities at every stage of a medical product’s lifecycle, from research and development through clinical trials and continuous monitoring after approval.
They engage with regulatory authorities to navigate a fast-paced innovation ecosystem to deliver game-changing medical products.
IFPMA represents the members of our industry, articulates its collective position, and collaborates with global regulatory bodies such as the World Health Organization.
Our experts produce position papers, policy and guidance documents, and other valuable tools that lead to greater understanding of how a strong, harmonized global regulatory system benefits people and populations, especially in under-resourced countries.
Collaboration, convergence, and regulatory reliance
IFPMA acts as a convener and encourages dialogues with national regulatory authorities (NRAs), regional regulatory bodies, and global regulatory networks to address key regulatory hurdles and identify solutions to facilitate patients’ timely access to innovative therapies.
Quality, safety, and efficacy of therapeutical products
IFPMA collaborates with the World Health Organization (WHO), regulatory, and other standard-setting bodies to share experience and scientific input and implement guidelines standardizing the quality of medicines and vaccines.
Biotherapeutics and advanced therapies
IFPMA spotlights how the innovative pharmaceutical industry is delivering a new generation of treatments while explaining the science-based regulatory requirements needed to make sure they deliver maximum therapeutic impact.